Percheron Therapeutics regroups after clinical trial results; vows to continue to conserve cash and develop pipeline ...
Percheron Therapeutics' board of directors has written a letter to shareholders following failure of its phase 2b trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback